9) More and more weight loss "miracle" drugs have been showing up on the market lately and the FDA has a challenge to determine what drugs are safe in a variety of different categories. The drugs all target parts of the brain involved with appetite and satiety, and interfere with hunger signals; so they can reduce the chances that you'll overeat. All of these drug companies are making huge pushes in the pharmaceutical world for patients to ask for these prescriptions from their doctors. The makers of a new drug, Saxenda wish to make an injectable treatment specifically for people with a Body Mass Index (BMI) of at least 30. The makers of Saxenda are making the claim patients will lose an average of at least 10.15 pounds within one month even with no change in their dietary or exercise routine. The following data shows the weight loss (in pounds) from volunteers who participated in some initial medical studies: | 4.75 9.98 11.12 10.13 8.7 9.74 12.4 6.4 8.62 7.15 4.8 9.0 12.1 5.2 11.56 a) Create the claims Saxenda is making? b) Is this data significant? Justify your response! c) What would a Type I error mean in context? Who would be hurt from this mistake? d) Doctors are skeptical, because they feel this new drug might help kick start the mentality about eating, but are also worried about the idea that no change to dietary or exercise routine is dangerous. The doctors also want to know about the subjects in the study. Pre-human studies with this drug found minuscule change in rodent weight... proportional speaking the doctors believe Saxenda has a real weight loss potential of 7.5 pounds at the 5% significance level. What's the probability of making a Type Il error? Does this hurt the patient more or Saxenda (don't elaborate too much here)?

MATLAB: An Introduction with Applications
6th Edition
ISBN:9781119256830
Author:Amos Gilat
Publisher:Amos Gilat
Chapter1: Starting With Matlab
Section: Chapter Questions
Problem 1P
icon
Related questions
icon
Concept explainers
Topic Video
Question

AP Stats Practice ASSIGNMENT 

9) More and more weight loss "miracle" drugs have been showing up on the market lately and the FDA has a
challenge to determine what drugs are safe in a variety of different categories. The drugs all target parts of the
brain involved with appetite and satiety, and interfere with hunger signals; so they can reduce the chances that
you'll overeat. All of these drug companies are making huge pushes in the pharmaceutical world for patients to
ask for these prescriptions from their doctors. The makers of a new drug, Saxenda wish to make an injectable
treatment specifically for people with a Body Mass Index (BMI) of at least 30. The makers of Saxenda are making
the claim patients will lose an average of at least 10.15 pounds within one month even with no change in their
dietary or exercise routine. The following data shows the weight loss (in pounds) from volunteers who
participated in some initial medical studies:
4.75 9.98 11.12 10.13 8.7 9.74 12.4 6.4 8.62 7.15 4.8 9.0 12.1 5.2 11.56
a) Create the claims Saxenda is making?
b) Is this data significant? Justify your response!
c) What would a Type I error mean in context? Who would be hurt from this mistake?
d) Doctors are skeptical, because they feel this new drug might help kick start the mentality about eating, but are
also worried about the idea that no change to dietary or exercise routine is dangerous. The doctors also want to
know about the subjects in the study. Pre-human studies with this drug found minuscule change in rodent
weight... proportional speaking the doctors believe Saxenda has a real weight loss potential of 7.5 pounds at the
5% significance level. What's the probability of making a Type Il error? Does this hurt the patient more or
Saxenda (don't elaborate too much here)?
Transcribed Image Text:9) More and more weight loss "miracle" drugs have been showing up on the market lately and the FDA has a challenge to determine what drugs are safe in a variety of different categories. The drugs all target parts of the brain involved with appetite and satiety, and interfere with hunger signals; so they can reduce the chances that you'll overeat. All of these drug companies are making huge pushes in the pharmaceutical world for patients to ask for these prescriptions from their doctors. The makers of a new drug, Saxenda wish to make an injectable treatment specifically for people with a Body Mass Index (BMI) of at least 30. The makers of Saxenda are making the claim patients will lose an average of at least 10.15 pounds within one month even with no change in their dietary or exercise routine. The following data shows the weight loss (in pounds) from volunteers who participated in some initial medical studies: 4.75 9.98 11.12 10.13 8.7 9.74 12.4 6.4 8.62 7.15 4.8 9.0 12.1 5.2 11.56 a) Create the claims Saxenda is making? b) Is this data significant? Justify your response! c) What would a Type I error mean in context? Who would be hurt from this mistake? d) Doctors are skeptical, because they feel this new drug might help kick start the mentality about eating, but are also worried about the idea that no change to dietary or exercise routine is dangerous. The doctors also want to know about the subjects in the study. Pre-human studies with this drug found minuscule change in rodent weight... proportional speaking the doctors believe Saxenda has a real weight loss potential of 7.5 pounds at the 5% significance level. What's the probability of making a Type Il error? Does this hurt the patient more or Saxenda (don't elaborate too much here)?
Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 6 steps

Blurred answer
Knowledge Booster
Sample space, Events, and Basic Rules of Probability
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, statistics and related others by exploring similar questions and additional content below.
Recommended textbooks for you
MATLAB: An Introduction with Applications
MATLAB: An Introduction with Applications
Statistics
ISBN:
9781119256830
Author:
Amos Gilat
Publisher:
John Wiley & Sons Inc
Probability and Statistics for Engineering and th…
Probability and Statistics for Engineering and th…
Statistics
ISBN:
9781305251809
Author:
Jay L. Devore
Publisher:
Cengage Learning
Statistics for The Behavioral Sciences (MindTap C…
Statistics for The Behavioral Sciences (MindTap C…
Statistics
ISBN:
9781305504912
Author:
Frederick J Gravetter, Larry B. Wallnau
Publisher:
Cengage Learning
Elementary Statistics: Picturing the World (7th E…
Elementary Statistics: Picturing the World (7th E…
Statistics
ISBN:
9780134683416
Author:
Ron Larson, Betsy Farber
Publisher:
PEARSON
The Basic Practice of Statistics
The Basic Practice of Statistics
Statistics
ISBN:
9781319042578
Author:
David S. Moore, William I. Notz, Michael A. Fligner
Publisher:
W. H. Freeman
Introduction to the Practice of Statistics
Introduction to the Practice of Statistics
Statistics
ISBN:
9781319013387
Author:
David S. Moore, George P. McCabe, Bruce A. Craig
Publisher:
W. H. Freeman